Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Recordati is a European specialty pharmaceutical company focused on rare diseases and established branded products, with significant presence in Western Europe (Italy, France, Germany) and growing operations in Central/Eastern Europe, Turkey, and North Africa. The company operates through two divisions: Specialty & Primary Care (orphan drugs for rare metabolic and endocrine disorders) and Rare Diseases (treatments for conditions like cystinuria, homocystinuria, and hereditary tyrosinemia). Recent 25% stock decline reflects market concerns despite solid 12.4% revenue growth and strong 68% gross margins.
Recordati generates revenue through two distinct models: (1) High-margin orphan drugs with pricing power due to limited alternatives, small patient populations, and regulatory exclusivity - these products command premium pricing ($50,000-$200,000+ annual treatment costs estimated) with minimal price sensitivity; (2) Established branded generics and specialty products leveraging strong physician relationships and distribution networks in fragmented European markets where brand loyalty persists. The company acquires undervalued specialty assets, optimizes commercial infrastructure, and expands geographic reach. Gross margins of 68% reflect favorable product mix toward rare diseases. Operating leverage comes from spreading fixed R&D and commercial infrastructure across growing product portfolio.
Rare disease product pipeline progress and regulatory approvals in EU/US markets - orphan drug designations drive valuation premiums
Geographic expansion success rates in high-growth emerging markets (Turkey 15%+ pharma growth, North Africa, Russia/CIS region)
M&A activity and asset acquisition multiples - Recordati historically acquires specialty assets at 3-5x sales, integrates into existing infrastructure
European pharmaceutical pricing and reimbursement policy changes - government healthcare budget pressures in Italy, France, Spain
Currency headwinds from Turkish lira, Russian ruble exposure given emerging market revenue concentration
European pharmaceutical pricing pressure intensifying as governments (Italy, France, Spain) implement austerity measures and mandatory price cuts on reimbursed medicines - rare disease products partially shielded but specialty/primary care segment vulnerable
Patent cliffs and loss of exclusivity on key rare disease products - Carbaglu and other orphan drugs face potential biosimilar competition as regulatory pathways evolve, though small markets limit generic entry incentives
Regulatory risk from evolving orphan drug designation criteria and pricing scrutiny - EU authorities increasingly challenging high orphan drug prices despite small patient populations
Large pharma companies (Takeda, Sanofi, Alexion/AstraZeneca) increasingly targeting rare disease space with superior R&D budgets and global commercial infrastructure
Gene therapy and curative treatments emerging for metabolic disorders could obsolete enzyme replacement and substrate reduction therapies in Recordati's portfolio within 5-10 years
Regional competitors in Turkey and Eastern Europe with lower cost structures and government relationships challenging market share in growth markets
Negative free cash flow of -$0.3B unsustainable - elevated $0.9B capex (39% of revenue) must normalize or revenue growth must accelerate to restore cash generation
Currency translation risk from Turkish lira, Russian ruble, and other emerging market exposures - 20-30% estimated revenue from non-EUR markets creates earnings volatility
Acquisition integration risk - historical M&A strategy requires successful commercial execution and synergy realization to justify purchase multiples
low - Pharmaceutical demand, especially for rare disease treatments, is non-discretionary and largely insulated from economic cycles. Patients with life-threatening metabolic disorders continue treatment regardless of GDP growth. However, OTC segment (~15-20% of revenue) shows modest correlation to consumer spending. Government healthcare budgets face pressure during recessions, potentially impacting reimbursement rates in Southern Europe.
Rising rates create modest headwinds through two channels: (1) Higher discount rates compress valuation multiples for long-duration pharma cash flows, particularly impacting rare disease assets with 10-15 year exclusivity periods; (2) Increased financing costs for M&A activity, though current 0.17 debt/equity ratio provides substantial capacity. EUR-denominated debt benefits from ECB policy divergence from Fed. Valuation compression likely explains portion of recent 25% decline.
Minimal - Strong balance sheet with 0.17 debt/equity, 1.64 current ratio, and 19.3% ROA indicates low refinancing risk. Pharmaceutical receivables from government health systems carry some payment delay risk in Southern Europe (Italy, Spain) but limited default risk. No meaningful exposure to consumer credit conditions.
value - Current 3.8x P/S and 11.5x EV/EBITDA multiples appear reasonable for 12.4% revenue growth and 27.3% operating margins, especially after 25% decline. Attracts investors seeking European healthcare exposure with rare disease growth optionality at reasonable valuations. 21.1% ROE and strong margins appeal to quality-focused value investors. Limited US institutional ownership due to Italian listing and EUR denomination.
moderate - Healthcare sector provides defensive characteristics, but mid-cap size ($10B market cap), European domicile, emerging market exposure, and M&A activity create volatility. Recent 25% decline over 6 months indicates elevated volatility period. Currency fluctuations from TRY and RUB exposure add earnings unpredictability. Beta likely 0.7-0.9 range relative to European healthcare indices.
